next generation sequencing assay (Adaptive Biotechnologies Corp)
86
Structured Review
Adaptive Biotechnologies Corp
next generation sequencing assay
Next Generation Sequencing Assay, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+assay/immunoseq+platform/pmc13155964-177-16-20
Average 86 stars, based on 1 article reviews
Next Generation Sequencing Assay, supplied by Adaptive Biotechnologies Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+assay/immunoseq+platform/pmc13155964-177-16-20
Average 86 stars, based on 1 article reviews
next generation sequencing assay - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Variant Assay:Article Title: Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome Article Snippet: .. To further assess the B-cell repertoire in asymptomatic POT1 pathogenic variant carriers, we used a high-resolution Article Title: Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome. Article Snippet: word count 250 Text word count 3965 Figure/table count 6 Reference count 56 D ow naded rom http://ashpublications.org/blood/art2/blood.2025031287/2499575/blood.2025031287.pdf by gest on 27 Jauary 2026 Next-Generation Sequencing:Article Title: Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome Article Snippet: .. To further assess the B-cell repertoire in asymptomatic POT1 pathogenic variant carriers, we used a high-resolution Article Title: Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome. Article Snippet: word count 250 Text word count 3965 Figure/table count 6 Reference count 56 D ow naded rom http://ashpublications.org/blood/art2/blood.2025031287/2499575/blood.2025031287.pdf by gest on 27 Jauary 2026 Article Title: Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Article Snippet: The outcomes of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the 3 main classes of myeloma therapy—immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies—remain poor.. Recently, based on the phase II pivotal KarMMa trial showing prolonged overall survival (OS) and progressionfree survival (PFS) in heavily treated patients, idecabtagene vicleucel (ide-cel), a B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy (CAR-T) product, was approved in the United States for the treatment of RRMM.. In France, since June 2021, an early access program has authorized the use of ide-cel in the setting of RRMM (defined as progressive myeloma after at least 3 previous regimens, including the 3 main antimyeloma therapies). |